Faculty UTCI

Raymond Uyiosa Osarogiagbon, MD, FACP

EDUCATION:

    • Undergraduate: College of Medicine, University of Ibadan, Nigeria, MBBS Degree, 10/82 – 07/88

 

    • Rotating Internship: University College Hospital, Ibadan, Nigeria, 07/88 – 07/89

 

    • Nigerian National Youth Service Corps: Nassarawa Hospital, Kano, Nigeria, 10/89 – 09/90

 

    • Internal Medicine Internship: Texas Tech University Health Sciences Center, Amarillo, TX, 07/93 – 06/95

 

    • Chief Resident, Internal Medicine: Texas Tech University Health Sciences Center, Amarillo, TX, 07/94 – 06/95

 

    • Hematology/Oncology Fellowship: University of Minnesota, Mineapolis, MN, 07/95 – 06/98

 

  • Completion of Research Project in the lab of Robert P. Hebbel, University of Minnesota, 07/98 – 12/98

 

HONORS/AWARDS:

    • Memphis Magazine America’s Best Doctors Award - 2010

 

    • Memphis Magazine America’s Best Doctors Award – 2009

 

    • Memphis Magazine America’s Best Doctors Award - 2008

 

    • Louise Evans Bruce Award, Texas Tech University, “Continued and invaluable support of the mission and vision of the Texas Tech University Health Sciences Center at Amarillo Medical School”, 03/04

 

    • Alpha Omega Alpha Honor Medical Society – 1995

 

    • Outstanding Resident of the Year, Texas Tech University – 1995

 

    • Certificate of Commendation – National Youth Service Corps of Nigeria, “exemplary dedication and service”, 1990

 

  • Award of Honor, University of Ibadan Medical Student’s Association – 1986

 

BOARD CERTIFICATION:

  • Diplomat of the American Board of Internal Medicine - #160593
    Hematology – 1999; recertified 2009
    Oncology – 1999; recertified 2009
    Internal Medicine – 1995

 

STATE MEDICAL LICENSURE:

  • Minnesota #38465. Issued 1995. Active
  • Texas #L0474. Issued 2000. Active
  • Tennessee #39287. Issued 2004. Active
  • Mississippi #18819. Issued 2004. Active

 

PROFESSIONAL MEMBERSHIPS:

  • Fellow of the American College of Physicians
  • American Society of Hematology
  • American Association for Cancer Research
  • International Association for the Study of Lung Cancer
  • Cardiothoracic Surgery Network (CTSNet)
  • Association of Specialty Professors (ASP)

 

 

 

UNIVERSITY APPOINTMENTS:

06/09 – Present

Present Associate professor (tenured), University of Tennessee Health Sciences Center, Memphis, TN

 

   

02/05 – 06/09

Assistant Professor of Medicine, University of Tennessee Health Science Center, Memphis, TN

 

   

ADMINISTRATIVE EXPERIENCE:

06/10 – Present

Present Associate professor (tenured), University of Tennessee Health Sciences Center, Memphis, TN

 

   

07/08 – 06/01/10

Associate Fellowship Program Director, University of Tennessee, Memphis, TN

 

07/08 – Present

Present Associate Clinical Research Director, University of Tennessee Cancer Institute, Memphis, TN

 

   

01/06 – Present

Present Director Multidisciplinary Thoracic Oncology Program, University of Tennessee, Memphis, TN

 

08/02 – 01/05

Chief of Medicine, Amarillo Veterans Affairs Health Care System, Amarillo, TX

 

HOSPITAL APPOINTMENTS:

02/05 – Present

Methodist Healthcare University Hospital, Memphis, TN

   

02/05 – Present

Methodist Healthcare North, Memphis, TN

02/05 – Present

Methodist Healthcare Germantown, Germantown, TN

   

02/05 – Present

Regional Medical Center at Memphis, TN

02/05 – Present

Veterans Affairs Medical Center, Memphis, TN

02/05 – Present

Baptist Memorial Hosptial East, Memphis, TN

02/05 – Present

Baptist Women’s Hospital, Memphis, TN

02/05 – Present

Baptist DeSoto Hospital, Southaven, MS

02/05 – Present

St. Francis Hospital, Memphis, TN

02/05 – Present

St. Francis Bartlett Hospital, Bartlett, TN

 

   
 

PRACTICE / PROFESSIONAL EXPERIENCE:

2006 - Present

Director, Adult Sickle Cell Program,
University of Tennessee Cancer Institute, Memphis, TN

 

   

02/05 – Present

Hematologist, Medical Oncologist,
University of Tennessee Cancer Institute, Memphis, TN

 

   

2005 – Present

Coordinator, Memphis Oncology Journal Club (MOJC)

 

   

2005 – Present

Hematology Oncology Fellowship Program Committee Member,
University of Tennessee

 

   

08/03 – 07/04

Chairman, Veterans Integrated Service Network (VISN)
18 Cardiology Action Team

 

   

2002 – 2004

Chairman, Blood Utilization Committee,
Amarillo Veterans Affairs Health Care System

 

   

2000 – 2004

Chairman, Invasive Pathology and Tissue Review Committee

 

   

1999 – 2004

Director, Continuing Medical Education Program,
Amarillo Veterans Affairs Health Care System

 

   

1994 – 1995

Chief Resident, Internal Medicine,
Texas Tech University, Amarillo, TX

 

   

TEACHING EXPERIENCE:

11/5/10

Course Director, Eigth Annual Mid-South Cancer Symposium.

 

   

10/09

Course Director, Seventh Annual Mid-South Cancer Symposium, ‘Quality Matters: Standardization of Quality Care in Oncology’, FedEx Institute of Technology, Memphis, TN

 

   

11/7/08

Course Co-Director, Sixth Annual Mid-South Cancer Symposium, ‘Multi Modality Therapies of Common Solid Tumors- Focus on Head & Neck Cancer’, FedEx Institute of Technology, Memphis TN

 

   

04/08

Moderator, Tenth Annual Palm Beach Cancer Symposium, ‘Practical Issues in Patient Care’, Palm Beach, FL

 

   

10/07

Course Co-Director, Fifth Annual Mid-South Cancer Symposium, ‘Focus on Thoracic Oncology’, FedEx Institute of Technology, Memphis, TN

 

   

04/07

Moderator, Thoracic Oncology Session, Nineth Annual Palm Beach Cancer Symposium, ‘Tailoring Treatment with Targeted Therapies’, Palm Beach, FL

 

   

2008 – Present

Molecular Basis of Disease (MBOD) lecture series for 1st Year Medical Students
Lectures Include:

 

   

2006 – Present

University of Tennessee Hematology Pathophysiology Course for 2nd Year Medical Students
Lectures Include:

    • CLL, Myeloma, Waldenstrom’s Macroglobulinemia and Hairy Cell Leukemia: A Quartet of Cousins – 02/25/08

 

    • Evaluating the person with a low red blood cell count - 02/18/08

 

    • Hemoglobin variants and the clinical problems they cause – 02/14/08

 

    • CLL, Multiple Myeloma, Waldenstrom Macroglobulinemia – 02/26/07

 

    • What is anemia and how to evaluate – 02/19/07

 

    • Evaluation of Anemia – 02/20/06

 

    • Hemolysis – 02/20/06

 

  • Hemoglobinopathies and Thalassemia – 02/15/06

 

   

2005 – 2008

University of Tennessee Internal Medicine Core Curriculum Lectures
Lectures Include:

    • Management of Sickle Cell Disease – 12/18/07

 

    • Oncologic Emergencies – 10/07/06

 

    • Hemoglobinopathy – 6/21/05

 

  • Oncologic Emergencies – 04/19/05

 

2005 – Present

University of Tennessee Hematology/Medical Oncology Fellowship Program Teaching Staff
Annual Lecture course load cover all of:

    • Colon and rectal cancer

 

    • Esophageal cancer

 

    • Gastric Cancer

 

    • Non-small cell lung cancer

 

  • Hemoglobinopathy

 

 

2005 – Present

University of Tennessee Pulmonary Division Chest Conference – Multiple Presentations

 

2005 – Present

University of Tennessee Cancer Institute Noon Journal Club – Multiple Presentations

 

1999 – 2006

Amarillo Veterans Affairs Medical Center Decision Tumor Board Conference – Multiple Presentations

 

1996 – 1998

Teaching Assistant, University of Minnesota Spring Blood Course, Minneapolis, MN

 

1996 – 1998

University of Minnesota Garibaldi Research Conference – Multiple Presentations

 

1995 – 1998

University of Minnesota Grand Rounds – Multiple Presentations

 

1995 – 1998

Minneapolis Veterans Affairs Medical Center Grand Rounds – Multiple Presentations

 

1995 – 1998

Hennepin County Medical Center Grand Rounds – Multiple Presentations

 

GRAND ROUNDS AND OTHER INTRAMURAL PRESENTATIONS:

1/21/09

‘The Quality of Surgical Resection for Lung Cancer in the Memphis Metropolitan Area’, University of Tennessee Medicine Grand Rounds

 

8/29/08

‘Management of Colorectal Liver Metastases’, University of Tennessee-Chattanooga Grand Rounds.

 

08/22/07

‘The Multidisciplinary Thoracic Oncology Clinic’, University of Tennessee Medicine Grand Rounds

 

08/01/07

‘Management of Superior Sulcus Tumors’, Methodist University Hospital Tumor Conference

 

02/24/06

‘The Vasculopathy of Sickle Cell Disease’, University of Tennessee Endocrinology Grand Rounds

 

11/30/05

‘Evolving Ideas About Sickle Cell Disease: Old Wine, New Skin’, University of Tennessee Medicine Grand Rounds

 

04/21/04

‘Understanding United States Cancer Statistics’, Texas Tech University Health Science Center Grand Rounds

 

01/19/03

‘Heparin-Induced Thrombocytopenia’, Texas Tech University Health Science Center Grand Rounds

 

04/24/02

‘Ignorant Armies Clash by Night: The Antiphospholipid Antibody Syndrome’, Texas Tech University Health Science Center Grand Rounds

 

09/25/00

‘Approach to the Bleeding Patient’, Texas Tech University Health Science Center Grand Rounds

 

11/98

‘Bad Humors from Dying Cancer Cells: Tumor Lysis Syndrome’, Texas Tech University Health Science Center Grand Rounds

 

07/97

‘The Hypereosinophilic Syndrome’, Texas Tech University Health Science Center Grand Rounds

 

VISITING PROFESSORSHIPS AND INVITED LECTURES:

    1. Amarillo, Tx. September 2010, “Lung Cancer: From Nodule to Diagnosis”, Texas Tech University Fall Cancer Symposium Visiting Professor.

 

    1. San Francisco, CA, August 1, 2009, “Surgery Allowing Neoadjuvant Treatment of N2 NSCLC”, Discussant at proffered paper session, 13th World Conference on Lung Cancer.

 

    1. Memphis, TN, September 2008, “Preventive Care for the Sickle Cell Patient”, First Annual Health Fair and Sickle Cell Awareness Day, National Civil Rights Museum.

 

    1. Memphis, TN, September 2008, “Managing Sickle Cell Disease as a Chronic Health Problem”, First Annual Health Fair and Sickle Cell Awareness Day, National Civil Rights Museum.

 

    1. Palm Beach, FL, April 2008, “Setting Up Thoracic Multidisciplinary Clinics: The University of Tennessee Cancer Institute Experience”, Tenth Annual Palm Beach Cancer Symposium.

 

    1. Memphis, TN, October 2007, “The Mid-South Thoracic Multidisciplinary Clinic: Implementation and Results”, Fifth Annual Mid-South Cancer Symposium: Focus on Thoracic Oncology.

 

    1. Amarillo, TX, September 2007, “Screening for Lung Cancer: Past, Present and Future”, Amarillo Fall Cancer Symposium Visiting Professor.

 

    1. Memphis, TN, September 2005, “Treatment Strategies for Transfusional Iron Overload”, Memphis Oncology Journal Club.

 

    1. Memphis, TN, May 2005, “Cancer Prevention and Screening”, American Cancer Society Public Information Symposium.

 

    1. Amarillo, TX, April 2005, “Epidemiology of Lung Cancer”, Texas Tech University/American Cancer Society Lung Cancer Symposium.

 

    1. Memphis, TN, May 2004, “The Early Multidisciplinary Approach to Lung Cancer”, University of Tennessee Cancer Institute.

 

    1. Amarillo, TX, November 2003, “Prometheus Bound: Screening for Lung Cancer”, American Cancer Society Symposium.

 

    1. Amarillo, TX, June 2003, “Primary Care Symposium: Colorectal Cancer Screening Initiative”, Amarillo Veterans Affairs Healthcare System.

 

    1. Amarillo, TX, July 2001, “The Endothelial Biology of Sickle Cell Disease”, Texas Tech University Health Sciences Center.

 

  1. Minneapolis, MN, June 1999, Paper Presentation at the University of Minnesota Bone Marrow Transplant Research Conference.

 

ABSTRACTS PRESENTED IN THE US:

    1. Surgical lymph node clearance and pathologic evaluation in gastric cancer. A Khattak, JC Sachdev, MC Evangelist, J Denbo, W.S Orr, M Ul-Haq, A Farooq, AC Thompson, RA Dilawari, RU Osarogiagbon. Abstract #131, 2011 Gastrointestinal Cancers Symposium, San Francisco, CA. January 2011.

 

    1. A comparison of surgical resection for distal esophageal, gastroesophageal and proximal gastric cancer in the Memphis Metropolitan Area. MC Evangelist, WS Orr, M Ul-Haq, A Farooq, A Khattak, J Denbo, A Mahmoud, RA Dilawari, JC Sachdev, RU Osarogiagbon. Abstract #147, 2011 Gastrointestinal Cancers Symposium, San Francisco, CA. January 2011.

 

    1. Pattern of gastric cancer resection in the Memphis metropolitan area (MMA). Evangelist, Sachdev, Khattak, Denbo, Orr, Ul-Haq, Berry, O'Brien, Dilawari, Osarogiagbon. E-poster 14633, abstract #54690 presented at the American Society of Clinical Oncology annual meeting 2010.

 

    1. Maruyama index (MI) and outcomes of gastric cancer resection. Sachdev, Evangelist, Orr, Denbo, Khattak, Ul-Haq, Farooq, Thompson, Mahmoud, Osarogiagbon. J Clin Oncol 2010; 15s: 339s. Abstract #4154, presented at the American Society of Clinical Oncology annual meeting 2010.

 

    1. Evaluation of multidisciplinary (multiD) care in thoracic oncology. Phelps, Bankole, Sarwar, McFarlane, Osarogiagbon. J Clin Oncol 2010; 15s: 470s. Abstract #6093, presented at the American Society of Clinical Oncology annual meeting 2010.

 

    1. Surgeon-determined variability in quality of surgical resection of lung cancer. Ramirez, Farooq, Allen, Berry, O’Brien, Cole, Osarogiagbon. J Clin Oncol 2010; 15s: 531s. Abstract #7068, presented at the American Society of Clinical Oncology annual meeting 2010.

 

    1. Review of mediastinal lymph node examination (mLNE) in a lung cancer resection (LCR) cohort. Osarogiagbon, Allen, Farooq, O’Brien, Wu. J Clin Oncol 2010; 15s: 531s. Abstract #7070, presented at the American Society of Clinical Oncology annual meeting 2010.

 

    1. A single arm phase 2 study of enzastaurin in combination with erlotinib, both administered orally daily, to patients with advanced non-small cell lung cancer (NSCLC). Wakelee, Dubey, Krupitskaya, Osarogiagbon, Sanborn, Bernstein, Dudek, Latz, Yuan, Natale. Presented at the World Conference on Lung Cancer 2009: PD3.2.2

 

    1. Clinical implications and determinants of inaccurate pathologic staging of lung cancaer in a large US metropolitan area. Farooq, Allen, O’Brien, Ratliff, Ninan, Osarogiagbon. Presented at the World Conference on Lung Cancer 2009: PD6.5.2

 

    1. Number of lymph nodes examined and likelihood of lymph node positivity after resection of lung cancer. Osarogiagbon, Allen, Farooq, O’Brien, Spencer, Ratliff, Ninan. Presented at the World Conference on Lung Cancer 2009: 12.1.2

 

    1. Quantification of the difficulty of accruing patients into quality-restrictive post-resection clinical trials for non-small cell lung cancer (NSCLC). Allen, Farooq, Ramirez, Ninan, Osarogiagbon. Presented at the World Conference on Lung Cancer 2009: 12.3.3

 

    1. Objective review of surgeon reported lymph node dissection after resection of lung cancer in a US metropolitan area. Ninan, Wu, Allen, Farooq, Kernstine, Osarogiagbon. Presented at the World Conference on Lung Cancer 2009: C4.4

 

    1. Outcome of surgical resection for pathologic Nx and N0 non-small cell lung cancer (NSCLC). Osarogiagbon, Allen, Farooq, Ninan, Ratliff. Presented at the American Society of Clinical Oncology annual meeting 2009.

 

    1. Accuracy and comprehensiveness of pathology reportage after lung cancer resection. Farooq, Osarogiagbon, Allen, O’Brien, Spencer, Berry. Presented at the American Society of Clinical Oncology annual meeting 2009.

 

    1. Quality of surgical resection for non-small cell lung cancer (NSCLC) in a US metropolitan area. Allen, Osarogiagbon, Farooq, Ninan, O’Brien. Presented at the American Society of Clinical Oncology annual meeting 2009.

 

    1. A comparison of two models of care for lung cancer. Osarogiagbon, Ninan, McFarlane, Bankole, Smeltzer, Jahanzeb. J Clin Oncol 2008, ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2009: 17501.

 

    1. Pattern of Adjuvant Chemotherapy for Stage II Colon Cancer in a University-Based Oncology Practice. Khattak, Sachdev, Osarogiagbon. Orlando, FL, January 2008, Gastrointestinal Cancers Symposium.

 

    1. The Prevalence of Renal Dysfunction in Young Adults with Sickle Cell Disease. Osarogiagbon, Chismark. 49th ASH Annual Meeting and Exposition, Atlanta, GA 2007.

 

    1. Hand-Assisted vs Open Colectomy in a Non-tertiary Care Setting. Osarogiagbon, Ogbeide, Ogbeide, George. GI Cancers Symposium, Orlando, FL January 2007.

 

    1. Screening Experience of Patients Diagnosed with Colorectal Cancer (CRC). Osarogiagbon. Gastrointestinal Cancers Symposium, Hollywood, FL, January 2005.

 

    1. Burkitt’s Lymphoma Occurring Less Than One Month After Chemotherapy for H. Pylori-associated Diffuse Large Cell Lymphoma. Osarogiagbon. Annual Convention of the American Society of Hematology, New Orleans, LA, December, 1999.

 

    1. CMV Antigenemia after BMT: Risk Factors and Clinical Outcomes. Osarogiagbon, Defor, Erice, Weisdorf. American Society of Hematology Annual Convention. Miami Beach, FL, December 9, 1998.

 

    1. Evidence of Reperfusion Injury Physiology in a Transgenic Mouse Model of Sickle Cell Disease. Osarogiagbon, Choong, Paller, Vercelotti, Hebbel. American Society of Hematology Annual Convention. San Diego, CA, December 1997.

 

    1. Sickle Cell Anemia s an Example of Reperfusion Injury Physiology: Studies in Transgenic Mice. Osarogiagbon, Choong, Paller, Vercelotti, Hebbel. 25th Annual Meeting of the National Sickle Cell Program, Washington, DC, September 1997.

 

 

ABSTRACTS PRESENTED AT INTERNATIONAL MEETINGS:

    1. Palais des Congres de Paris, April 2008, “Implementation of a Multidisciplinary Clinic Care Model for Lung Cancer”, International Forum on Quality and Safety in Health Care.

 

    1. Seoul, South Korea, September 2007, “Concordance Between Recommendations of a Multidisciplinary Thoracic Oncology Conference and Actual Clinical Practice”, 12th World Conference on Lung Cancer.

 

    1. Barcelona, Spain, June 2005, “Comparison of Hand-assisted Laparoscopic and Open Colectomy for Colon Tumors”, World Congress on Gastrointestinal Cancer.

 

 

EDITORIAL APPOINTMENTS:

    • Associate Editor, Archives of Ibadan Medicine

 

    • Member, Faculty of 1000

 

  • Manuscript reviewer:
    Annals of Thoracic Surgery
    Diseases of the Esophagus
    Journal of Thoracic Oncology

 

EXTERNAL GRANT REVIEWER FOR FUNDING AGENCY:

  • Randomized Controlled Trials Unit of the Canadian Institutes of Health Research

 

COMMITTEES:

    • National Comprehensive Cancer Network Esophageal Guidelines Panel (2005 – present)

 

    • National Comprehensive Cancer Network Gastric Guidelines Panel (2005 – present)

 

    • National Comprehensive Cancer Network Genetic/Familial High Risk Assessment Guidelines Panel (2005-2008)

 

    • National Comprehensive Cancer Network Non-Small Cell Lung Cancer Guidelines Panel (2008 - present)

 

    • American Society of Hematology Outreach Sub-Committee on Africa (1999-2001)

 

    • Southwest Oncology Group Health Disparities Committee.

 

    • Southwest Oncology Group Gastrointestinal Cancers Committee.

 

    • Southwest Oncology Group Lung Cancer Committee.

 

  • University of Tennessee Fellowship Training Program Committee

 

FELLOWS TRAINED:

  • 07/08 – Present Makenzi Evangelist
  • 07/08 – Present Adam Leikensohn
  • 07/08 – Present Muhammad Raza
  • 07/08 – Present Robert Ramirez
  • 07/07 – Present Krishna Alluri, private practice, Florida
  • 07/07 – Present Claudia Paba, Dana Farber Cancer Institute, Boston, MA
  • 07/07 – Present Andrew Schreiber, private practice, North Carolina
  • 08/06 – Present Shehzad Azmi, private practice,
  • 07/06 – Present Saira Ahmed, private practice, Maryland
  • 07/06 – Present Josh McFarlane, private practice, Virginia Cancer Institute, Richmond, VA
  • 01/06 – Present Salil Goorha, Assistant Professor, University of Tennessee.
  • 07/05 – 06/08 Jeffrey Allen, Assitant Professor, University of Tennessee.
  • 07/05 – 06/08 Gregory Franz, private practice, Georgia.
  • 07/05 – 08/08 Arshad Husain, private practice, Kentucky.
  • 02/05 – 06/07 Jasgit Sachdev, Assitant professor, University of Tennessee.
  • 02/05 – 06/07 Sarah Waheed, Assistant professor, University of Arkansas, Little Rock.
  • 02/05 – 06/06 Sal Vasireddy, UTCI faculty member.
  • 02/05 – 06/06 Naveed Aslam, private practice, Michigan.
  • 02/05 – 06/06 Brian McClune, Assistant professor, University of Minnesota.
  • 02/05 – 12/05 Sonia Benn, private practice, Memphis, TN.

 

RESIDENTS / MEDICAL STUDENTS MENTORED:

  • 07/08 – 06/09 Raquel Spencer
  • 07/08 –06/09 Daniel Magro
  • 07/08 – 06/09 Jordan Masters
  • 07/08 – 06/09 Patrick Mastin
  • 07/07 –06/09 Christopher Shaw
  • 07/07 – 06/08 Anna Chandler
  • 07/07 – 06/08 Dana Hensley
  • 07/07 – 06/08 Andrew Wooldridge
  • 07/07 – 06/08 Brian Fuller

 

OTHERS MENTORED:

    • Laura Beth Miller, MD. Department of Medicine, University of Tennessee, Memphis.

 

    • Christopher Wang, MD. Department of Medicine, University of Tennessee, Memphis.

 

    • Aamer Farooq, MD. Roswell Park Cancer Institute, Buffalo NY.

 

    • Olufunsho Bankole, MBBS. Division of Pulmonary and Critical Care Medicine. University of Tennessee, Memphis.

 

    • Elisabeth Chismark, UT College of Nursing, successful nursing Phd candidate. I co-mentored her project titled ‘Characteristics of secondary complications and the association of serum c-reactive protein levels and a genetic c-reactive protein polymorphism in adult sickle cell patients’ with Ann Cashion, Phd.

 

    • Jianquan Zhu, MD, Thoracic Surgeon, Guangdong Provincial People’s Hospital, Guangzhou, Guangdong, China. June 2008. American Society of Clinical Oncology (ASCO) International Development and Education Award (IDEA) Program.

 

  • Roderigo Dienstmann, Medical Oncologist, National Institutes of Health of Brazil. June 2007 ASCO IDEA Program.

 

RESEARCH AND OTHER EXTERNAL SUPPORT:

    1. Feasibility study of the use of special specimen collection kit to improve lymph node yield during surgical resection of non-small cell lung cancer. Funded by the Methodist Healthcare Foundation. $30,000. Ongoing.

 

    1. Systematic Review of the Product of Surgical Resection in the Memphis Metropolitan Area (MMA): OSI-TAR-763. Funded to $55,750. Principal Investigator. On-going project.

 

    1. Phase II multicenter study of temsirolimus in patients with advanced hepatocellular cancer (HCC) previously treated with sorafenib. Principal Investigator: Jasgit Sachdev, MD, Raymond Osarogiagbon, MD. Funding Agency: Wyeth Pharmaceuticals. Funding approved to $298,170.

 

 

CURRENT RESEARCH INTERESTS:

    • The relationship between models of care, access and outcomes in the management of lung cancer.

 

    • The determinants of the pattern and quality of surgical resection for lung cancer, esophageal and gastric cancer.

 

    • The pattern of use of adjuvant chemotherapy for colon cancer.

 

    • Implementation of an adult sickle cell program in the greater Memphis area, in collaboration with St. Jude Children’s Research Hospital’s Comprehensive Sickle Cell Program.

 

  • Dilineating the full picture of cumulative and chronic organ damage in sickle cell disease.

 

PRINCIPAL INVESTIGATOR:

  • National Cancer Institute Investigator number: 28258
  • Southwest Oncology Group investigator number: 34995
  • Institutional Principal Investigator (University of Tennessee) for the Southwest Oncology Group (SWOG)

 

Lung Cancer

    1. E1505: Chemotherapy with or without bevacizumab in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery. National Cancer Institute-sponsored trial under the auspices of the Eastern Cooperative Oncology Group. ClinicalTrials.gov identifier: NCT00324805.

 

    1. SWOG 0533: A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer. Southwest Oncology Group and National Cancer Institute-sponsored trial. ClinicalTrials.gov identifier: NCT00334815.

 

    1. OSI 774-302: RADIANT: A Multi-Center Ranodmized, Double-Blind, Placebo-Controlled, Phase III Study of Single-Agent Tarceva (erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-Small Cell Lung Carcinoma who have EGFR-positive Tumors. Sponsored by OSI Pharmaceuticals. ClincalTrials.gov identifier: NCT00373425.

 

    1. Lilly H6Q-MC-S030: A Phase I/II Trial of Enzastaurin and Erlotinib in Patients with Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) after Prior Chemotherapy.

 

    1. GSK HYT11127: An Open-label, Multicenter, Non-comparative, Phase II Study of Oral Topotecan in Combination with Bevacizumab for Second-line Treatment in Subjects with Relapsed Small-Cell Lung Cancer (SCLC).

 

  1. Merck 056-02: A Phase II/III Randomized, Double-Blind Study of Paclitaxel Plus Carboplatin in Combination with Vorinostat (MK-0683) or Placebo in Patients with Stage IIIB (with pleural effusion) or Stage IV Non-Small Cell Lung Cancer (NSCLC).

 

Colorectal Cancer

    1. CALGB 80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucorovin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum. National Cancer Institute-sponsored intergroup trial. ClinicalTrials.gov identifier: NCT00265850.

 

    1. SWOG 0600: Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer Who Have Progressed on Bevacizumab with Either FOLFOX, Optimox or XeLOX. National Cancer Institute-sponsored intergroup trial. ClinicalTrials.gov identifier: NCT00499369.

 

    1. ECOG E5204: Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pro-Operative Chemoradiation.

 

  1. NSABP R-04: A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum.

 

Investigator-Initiated Research

    1. Anaplastic lymphoma kinase (ALK) gene mutation profiling in upper aerodigestive tract malignancies.

 

    1. A feasibility study of the use of a special specimen collection kit to improve lymph node yield during surgical resection of non-small cell lugn cancer.

 

    1. Pathologic examination of resected lung cancer: A pilot study to improve staging.

 

    1. Systematic Review of the Product of Surgical Resection of Lung Cancer in the Memphis Metropolitan Area (MMA): funded by OSI. Budget: $55,750

 

    1. Concordance Between Management Recommendations of a Multidisciplinary Lung Cancer Board and Clinical Management.

 

    1. Healthcare disparities and lung cancer: The Memphis experience: moderating disparities by means of the early multidisciplinary model of care.

 

    1. Phase II trial of bevacizumab + standard platinum-based combination chemotherapy and radiation therapy for non-surgically resectable stage IIIA and IIIB non-small cell lung cancer.

 

    1. Impact of adjuvant chemotherapy on 5-year survival outcomes of patients with stage IIB vs. IIIA colon cancer: a SEER/Medicare linked database analysis.

 

    1. Prevalence and predictors of chronic organ damage in adults with sickle cell disease.

 

 

PUBLICATIONS:

    1. Pathologic lymph node staging practice and stage-predicted survival after resection of lung cancer. Osarogiagbon RU, Allen JW, Farooq A, Berry A, O’Brien T. Accepted for publication in the Annals of Thoracic Surgery.

 

    1. Causes and consequences of deviation from multidisciplinary care in thoracic oncology. Osarogiagbon RU, Phelps G, McFarlane J, Bankole O. Accepted for publication in the Journal of Thoracic Oncology.

 

    1. Quality of surgical resection for nonsmall cell lung cancer in a US metropolitan area. Allen JW, Farooq A, O'Brien TF, Osarogiagbon RU. Gastric cancer. Cancer. 2011;117:134-42. Published online August 24, 2010. DOI 10.1002/cncr.25334. PMID: 20737568.

 

    1. Thymic Malignancies. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC. J Natl Compr Canc Netw. 2010 Nov 1;8(11):1302-1315. PMID: 21081786

 

    1. Non-small cell lung cancer. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC. J Natl Compr Canc Netw. 2010 Jul;8(7):740-801.

 

    1. Ajani, Barthel, Bekaii-Saab, Bentrem, D’Amico, Das, Denlinger, Fuchs, Gerdes, Hayman, Hazard, Hofstetter, Ilson, Keswani, Kleinberg, Korn, Meredith, Mulcahy, Orringer, Osarogiagbon, Posey, Sasson, Scott, Shibata, Strong, Washington, Willett, Wood, Wright, Yang. J Natl Compr Canc Netw 2010 Apr; 8 (4): 378-409.

 

    1. Outcome of Surgical Resection for Pathologic N0 and Nx Non-Small Cell Lung Cancer, Osarogiagbon, Allen, Farooq, Berry, Spencer, O’Brien. J Thorac Oncol. 2010 Feb;5(2):191-6.

 

    1. Pattern of use of adjuvant chemotherapy for stage II colon cancer. Osarogiagbon, Sachdev, Khattak, Kronish. Clinical Colorectal Cancer, Mar 2008; 8(2): 94-9.

 

    1. Esophageal cancer. Ajani, Barthel, Bekaii-Saab, Bentrem, D’Amico, Fuchs, Gerdes, Hayman, Hazard, Ilson, Kleinberg, McAleer, Meropol, Mulcahy, Orringer, Osarogiagbon, Posey, Sasson, Scott, Shibata, Strong, Swisher, Washington, Willett, Wood, Wright, Yang. J Natl Compr Canc Netw. 2008 Oct; 6(9): 818-49.

 

    1. Hand-assisted Laparoscopic Colectomy Compared With Open Colectomy in a Non-tertiary Care Setting, Osarogiagbon, RU, Ogbeide O, Ogbeide E., Clin Colorectal Cancer. 2007 Jul;6(8):588-92.

 

    1. Gastric Cancer Clinical Practice Guidelines. Ajani, Bekaii-Saab, D’Amico, Fuchs, Gibson, Goldberg, Hayman, Ilson, Javle, Kelley, Kurtz, Locker, Meropol, Minsky, Orringer, Osarogiagbon, Posey, Roth, Sasson, Swisher, Wood, Yen. J Natl Comprehensive Cancer Network. 2006 Apr;4(4):350-66.

 

    1. Esophageal Cancer Clinical Practice Guidelines. Ajani, Bekaii-Saab, D’Amico, Fuchs, Gibson, Goldberg, Hayman, Ilson, Javle, Kelley, Kurtz, Locker, Meropol, Minsky, Orringer, Osarogiagbon, Posey, Roth, Sasson, Swisher, Wood, Yen. J Natl Comprehensive Cancer Network. 2006 Apr 4(4):328-47.

 

    1. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Daly, Axilbund, Bryant, Buys, Eng, Friedman, Esserman, Farrell, Ford, Garber, Jeter, Kohlmann, Lynch, Marcom, Nabell, Offit, Osarogiagbon, Pasche, Reiser, Sutphen, Weitzel. J Natl Comprehensive Cancer Network. 2006 Feb;4(2):156-76

 

    1. The Endothelial Biology of Sickle Cell Disease: Inflammation and a Chronic Vasculopathy. Hebbel, Osarogiagbon, Kaul. Microcirculation 2004, 11: 129-151.

 

    1. Newer Concepts of the Pathogenesis of Sickle Cell Disorder: The Evidence for Inflammation. Osarogiagbon. Archives of Ibadan Medicine, October 2001, Volume 2, Number 2:41-45

 

    1. CMV antigenemia following bone marrow transplantation: risk factors and outcomes. Osarogiagbon, Defor, Erice & Weisdorf. Biology of Blood and Marrow Transplantation 2000, 6: 280-288

 

    1. Immunology in Cancer. Osarogiagbon. Archives of Ibadan Medicine 2000, 1: 20-24

 

    1. Reperfusion injury physiology in sickle transgenic mice. Osarogiagbon, Choong, Belcher, Vercellotti, Paller & Hebbel. Blood 2000, 96: 314-320.

 

  1. Chronic Myelogenous Leukemia. Osarogiagbon & McGlave. Current Opinion in Hematology 1999, 6:241-246

 

OTHER PUBLICATIONS (EDITORIAL COMMENTARY):